Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2018-05-22T18:49:10-0400
This study evaluates the safety of acalabrutinib and AZ6738 when taken in combination.
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalum...
The goal of this clinical research study is to learn if AZD9150 given in combination with MEDI4736 (durvalumab) can help to control advanced pancreatic, lung, or colorectal cancer.
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma....
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design...
The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the...
Acalabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously treated chronic lymphocytic leukemia (CLL), how...
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that poses a clinical challenge. Thus, new therapy strategies are urgently needed. The selective WEE1 inhibitor, AZ...
B cell receptor (BCR) signaling plays a key role in B cell development and function. Aberrant BCR signaling has been confirmed as a central driver for the pathogenesis of various B cell malignancies. ...
Bruton's tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Target...